26 June 2026, Friday

24 June 2026, Wednesday

25 June 2026, Thursday

26 June 2026, Friday

27 June 2026, Saturday

26 June 2026, Friday
BOSPHORUS HALL TOPKAPI HALL GALATA HALL TAKSİM HALL KADIKÖY HALL A3 ROOM STONE Amphitheatre CASE 2 BEBEK POSTER HALL MODA POSTER HALL BEŞİKTAŞ POSTER HALL
07:00-07:30 EPC PANCREATIC CANCER RUN, Caddebostan Beach
07:00-08:30
07:00-07:30
07:30-08:30 EPC Public Affairs Committe Börek with the Professors 07:30-08:30
08:30-09:45 Translational Breakthroughs in Pancreatology & EPC -Lifetime Achievement Award Lecture & Palade Prize Lecture Why Pediatric to Adult Integration Matters in Pancreatic Diseases Hands-On Workshop 08:30-09:45
09:45-10:15 09:45-10:15
10:15-10:45 Satellite Symposium COFFEE BREAK & SPONSORS EXHIBITION EPC & JPS
10:15-10:45
10:45-13:00 Live Advanced-EUS     & Extended EUS  Procedures Best  Abstracts Cystic Tumors & PanNET The Fatty Pancreas International Consensus Report: Lessons Learned and Roadmap for the Future TRANSPAN Hands-On Workshop 10:45-13:00
13:00-14:00 LUNCH BREAK & POSTER ROUNDS & SPONSORS EXHIBITION 13:00-14:00
14:00-15:45 Early Detection & Treatment of Pancreatic Cancer Best Abstracts Pancreatitis & Endoscopy

Best Abstracts

Varia-II

PANDoRA Consortium Hands-On Workshop 14:00-15:45
15:45-16:15 Satellite Symposium IAP – General Assembly COFFEE BREAK & SPONSORS EXHIBITION 15:45-16:15
16:15-17:00 Rudolf Ammann & Best Abstracts Awardee Session Hands-On Workshop 16:15-17:00
17:00-18:30 EPC – General Assembly 17:00-18:30
BOSPHORUS HALL
08:30-08:50 IAP Palade Prize Lecture  Chairs: Vinciane Rebours, (Paris, France),  Min Li (Oklahoma City, USA)
  Acinar Cells: at the Heart of the Pancreas – and Mine Francisco X. Real (Madrid, Spain)
08.50-09.55
Translational Breakthroughs in Pancreatology  Chairs: Roland Rad (Munich, Germany), Min Li (Oklohoma City, USA), Reiner Heuchel (Stockholm, Sweden)
08.50-09.03 Decoding Pancreatic Cancer Ecosystems with Single-Cell and Spatial Omics William L. Hwang (Boston, USA)
09.03-09.16 Genotype-Guided Treatment of Pancreatic Cancer: Exploiting DNA Repair and Stromal Vulnerabilities Alexander Kleger (Ulm, Germany)
09.16-09.29 Vulnerabilities, and Clinical Translation Raghu Kalluri (Houston, USA)
09.29-09.42 Decoding Pancreatic Carcinogenesis: Genomic Roadmaps from Precursor Lesions to Invasive Cancer Laura D. Wood (Baltimore, USA)
09.42-09.55

Best Translational Abstracts

Local delivery of CAR T cells using fibrin glue enables cellular immunotherapy for pancreatic ductal adenocarcinoma

Tengis Tschaidse (Munich ,Germany)
09.55-10.15 EPC – Lifetime Achievement Awardee Lecture Chairs: Güralp O. Ceyhan (Istanbul, Turkiye), Gabriele Carpuso (Milan, Italy)
Why Basic & Translational Research is Dependent on the Clinician’s Eye – Even from a Surgeon! Helmut Friess (Munich, Germany)
10.15-10.45 Coffee Break Satellite Symposium (during the Coffee Break)
10.45-13.00 Live Advanced EUS & Extended EUS Procedures Chairs: Albrecht Neeße (Göttingen, Germany), Andrew Metz (Melbourne, Australia), Dilek Oğuz, (Ankara, Turkey) 
10.45-11.00 Global Perspective & Consensus: Expanding Roles of EUS Interventions within Surgical Care Pathways – Where are the Limits? Andrew Metz (Melbourne, Australia)
11.00-11.30 Live Endoscopy (Patient 1) Gürhan Sisman (Istanbul, Türkiye) & Pieter Hindryckx (Gent, Belgium)
11.30-11.45 EUS-Guided Phosphorus-32 Intratumoral Brachytherapy in Locally Advanced PDAC: Redefining Local Control & Downstaging Potential Stefano F. Crino (Verona, Italy)
11.45-12.15 Live Endoscopy (Patient 2) Gürhan Sisman (Istanbul, Türkiye) & Pieter Hindryckx (Gent, Belgium)
12.15-12.30 Artificial Intelligence in Pancreatic EUS: Where do We Stand? Adrian Saftoiu (Craiova, Romania)
12.30-13.00 Live Endoscopy (Patient 3) Gürhan Sisman (Istanbul, Türkiye) & Pieter Hindryckx (Gent, Belgium)
13.00-14.00 Lunch
14.00-15.45 Early Detection & Treatment in Pancreatic Cancer  Chair: Shounak Majumder (Rochester,USA), Masayuki Sho (Nara, Japan), Mert Erkan (Istanbul, Turkiye)
14.00-14.14 Liquid Biopsy for Early Detection of Pancreatic Cancer and Its Impact on Treatment Monitoring and Guiding Shounak Majumder (Rochester,USA)
14.14-14.28 MRI or EUS – What is the Best Modality to Screen for Early Pancreatic Cancer Stephen Philcox (President of Australian Pancreatic Club) (Newcastle, Australia)
14.28-14.42 Multidisciplinary Approaches and Survival Benefits of Surgery in Locally Advanced Pancreatic Cancer İhsan Ekin Demir (Munich, Germany)
14.42-14.56 Advanced Preoperative Imaging Techniques in Assessing Tumor Resectability Post-Neoadjuvant Therapy: Is Maging Ready to Help Us? Rickmer Braren (Hamburg, Germany)
14.56-15.10 Triangle & Advanced Vascular Resection in LAPC – Why It is a Must in LAPC Surgery? Shailesh Shrikhande (Mumbai, India)
15.10-15.30 When Resection then Minimally Invasive or Open? – what DIPLOMA Showed Us Marc G. Besselink (Amsterdam, Netherlands)
15.30-15.45 Optimal Dose of Pancreatic Enzyme Replacement Therapy (PERT) for Pancreatic Exocrine Insufficiency (PEI) in Different Pancreatic Diseases: European PEI Registry: Final Results Juan Enrique Dominguez Munoz (Santiago de Compostela, Spain)
15.45-16.15 Coffee Break Satellite Symposium (during the Coffee Break)
16.15-17.00 Rudolf Ammann & Best Abstracts Awardee Session Chairs: Güralp O. Ceyhan (Istanbul, Türkiye), Gabriele Capurso (Milan, Italy), Vinciane Rebours (Paris, France), Pramod Garg (New Delhi, India)
16.15-16.32

Rudolf Amman Award/ Nordmark

Heavy metals in cigarette smoke strongly inhibit pancreatic ductal function and promote development of chronic pancreatitis

Petra Pallagi (Szeged, Hungary)
16.32-16.39

Best Abstract Clinical Science/EPC

Normal Saline or Lactated Ringer’s Solution in Acute Pancreatitis Resuscitation: a multicenter randomized clinical trial (WATERLAND)

Lucia Guilabert (Elche, Spain)
16.39-16.46

Best Abstract Clinical Science/IAP

Spatial Transcriptomics Reveals Molecular Trajectories and Immune Landscapes in IPMN and IPMN-derived Pancreatic Cancer

Ming Cui (Beijing, China)
16.46-16.53

Best Abstract Basic Science/EPC

Hepatic Innervation as a Regulator of the Pre-Metastatic Niche and Liver Metastasis in Pancreatic Cancer

Eyük Yöndem (Munich, Germany)
16.53-17.00

Best Abstract Basic Science/IAP

A stem cell-engineered immune-competent PDAC organoid reveals CAF-lineage specific therapeutic vulnerabilities

Yujie Li (Sydney, Australia)
17.00-18.30 EPC – General Assembly
TOPKAPI HALL
08.30-09:50 Why Pediatric to Adult Integration Matters in Pancreatic Diseases Chairs: Sanjay Pandanaboyana (New Castle, UK), Maisam Abu-El-Heija (Cincinnati, USA)
08.30-08.45 CFTR-Associated and Other Pediatric Pancreas Diseases as a Bridge to Adult Care József Maléth (Szeged, Hungary)
08.45-09.00 Genetic Architecture of Pancreatitis: From Childhood Presentation to Adult Chronic Disease Andrea Geisz (Boston, USA)
09.00-09.15 Classification and Imaging of Pediatric Pancreatitis – Implications for Adult Practice Temel Tirkes (Indianapolis, USA)
09.15-09.30 What Pediatric Cohorts Teach Us About Lifelong Pancreatic Disease Maisam Abu-El-Haija (Cincinnati, USA)
09.30-09:45 Surgery of the Pediatric Pancreas, When It Can’t Wait till to Adolescence and What Type of Surgery then? Sanjay Pandanaboyana (Newcastle, UK)
10.15-10.45 Coffee Break
10.45-13.00 Best  Abstracts Cystic Tumors & PanNET Chairs: Stefano Partelli (Milan, Italy), Müjde Soytürk (Izmir, Turkiye)
10:45-10:54 Recurrence After Resection of Non-Invasive Intraductal Papillary Mucinous Neoplasms: A Multicenter Analysis of Risk Factors and Clinical Impact Riccardo Pellegrini (Padova ,Italy)
10:54-11:03 Optimizing pancreatic cyst surveillance: a cost-effectiveness analysis using microsimulation modelling Oliver White (Rotterdam ,The Netherlands)
11:03-11:12 Exposome and cyst features are associated with distinct histotypes and malignancy risk in surgically resected IPMNs: preliminary results from the multicenter ESPRESSO MACCHIATO study Gabriele Capurso (Milan ,Italy)
11:12-11:21 Decoding IPMN Heterogeneity: Matched Molecular Profiling from Cyst Wall, Fluid and Plasma in the GERPACYST Registry Matthäus Felsenstein (Berlin ,Germany)
11:21-11:30 Real-world EUS evaluation of pancreatic cystic lesions: cytology-based classification and predictors of mucinous cysts and high grade dysplasia Charalampos Thanos (Athens ,Greece)
11:30-11:39 Clinical, demographic and EUS features of pancreatic cysts: a nationwide multicenter study of the Pancreas Working Group  
11:39-11:48 Reappraisal of the concept of “timely surgery” according to follow-up vs upfront surgery strategy for IPMNs Riccardo Pellegrini (Padova ,Italy)
11:48-11:57 AI-based radiomics for pancreatic cysts: high diagnostic performance amid persistent translational gap Johannes D. Lettner (Freiburg ,Germany)
11:57-12:06 Complementary ex vivo models reveal determinants of targeted therapy response in nonfunctioning pancreatic neuroendocrine tumors Anna Battistella (Milano ,Italy)
12:06-12:15 More Parenchyma, Less Safety? Two Decades of Pancreatic Neuroendocrine Tumor Surgery Carola Focke (Freiburg ,Germany)
12:15-12:24 IRE-centered multidisciplinary treatment for unresectable pancreatic acinar-MiNEN: durable 5-year survival in an ultra-rare pancreatic malignancy Yingjie Wang (Zhengzhou ,China)
12:24-12:33 Multi-omics profiling of CUX1 transcription factor revealed epigenetic regulation in PanNETs: Unlocking new therapeutic targets through targeting the CUX1–HAT1/EZH2 pathway Maryam Khosravian (Heidelberg ,Germany)
12:33-12:42 Endoscopic Photodynamic Therapy Under Direct Visualization via Pancreatoscopy: An Innovative treatment for Pancreatic MD-IPMN Wei Liu (Changsha City ,China)
12:42-12:51 Evaluation of the treatment strategy for small non-functioning pancreatic neuroendocrine neoplasms: resection versus observation Wataru Izumo (Yamanashi ,Japan)
12:51-13:00 Primary Tumor Resection Prior to Peptide Radionuclide Receptor Therapy Improves Survival in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-analysis Sándor Orbán (Budapest ,Hungary)
13.00-14.00 Lunch
14.00-15.45 Best Abstracts Pancreatitis & Endoscopy Chairs: Erkin Öztaş (Istanbul, Turkiye), Livia Archibugi (Milan, Italy)
14.00-14.09 Pain in Chronic Pancreatitis: Multidimensional associations with neuropsychological factors, neurometabolic alterations, and corticolimbic connectivity Abdul Rasheed Mohammed (Hyderabad ,India)
14.09-14.18 Trajectories of pain processing in recurrent acute and chronic pancreatitis: a longitudinal quantitative sensory testing study Louise Kuhlmann (Aalborg ,Denmark)
14.18-14.27 Risk of pancreatic disease in families with metabolic dysfunction-associated steatotic liver disease: a population-based multigenerational cohort study Miroslav Vujasinovic (Stockholm ,Sweden)
14.27-14.36 Long term evolution of type 2 autoimmune pancreatitis, evidence from a large french cohort Clémence Descourvières (Clichy ,France)
14.36-14.45 Clinical Practice of Modified Pancreatic Duct Stone Classification (Xi-Panc) in the Treatment of Chronic Pancreatitis Xue Yang (Xi’an ,China)
14.45-14.54 Managed risk of abdominal compartment syndrome in patients with acute severe pancreatitis Ivanna A. Shchyhel (Kyiv ,Ukraine)
14.54-15.03 Combination of non-steroidal anti-inflammatory drugs plus pancreatic duct stent placement after unintentional pancreatic duct cannulation is superior to NSAIDs alone in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis Mike J.P. de Jong (Nijmegen ,The Netherlands)
15.03-15.12 Machine Learning versus QNI Score for Predicting Step-Up Therapy After Initial EUS-Guided Drainage of Pancreatic Fluid Collections Marcel Razpotnik (Berlin ,Germany)
15.12-15.21 International Delphi Consensus on Training in Diagnostic and Therapeutic Endoscopic Ultrasound Matteo Tacelli (Milano ,Italy)
15.21-15.30 Closing the ERCP quality gap: an open digital platform for real-time competency and outcome tracking Lukas Erhart (St. Pölten ,Austria)
15.30-15.39 Redefining vascular patterns in focal lesions with EUS Detective Flow Imaging: a multicenter interobserver agreement study Riccardo Di Pangrazio (Roma ,Italy)
14.00-15.54 Best Abstracts – Vatria II Chairs: Aydin Seref Köksal (Ankara, Turkiye), Laura Maggino (Verona, Italy)
14.00-14.09 Small intestinal bacterial overgrowth as a possible cause of falsely reduced fecal elastase-1 levels Natalya Gubergrits
14.09-14.18 A Patient-Reported Tool for All PEI Etiologies? Validation of the PEI-Q and Its Utility in Monitoring Response to PERT J Enrique Dominguez Muñoz
14.18-14.27 Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study Ana Dugic
14.27-14.36 10-year empirical survival rates following upfront pancreatectomy for pancreatic ductal adenocarcinoma. A bi-institutional analysis Susanna Tondato
14.36-14.45 Pre-Test Probability Drives the Diagnostic Yield of Fecal Elastase-1: A Multicenter Real-World Study Marta Andreozzi
14.45-14.54 The mouse cancer cell line atlas reveals core principles of tissue-specific cancer evolution Sebastian Mueller
14.54-15.03 Exocrine pancreatic insufficiency and nutritional status in resectable and borderline resectable periampullary tumors: A prospective longitudinal study Eric Herrero Fonollosa
15.03-15.12 Whole genome sequencing-using long-reads to identify structural variants and methylation signatures in IPMN evolution into malignancy Riccardo Farinella
15.12-15.21 Preoperative transhepatic portomesenteric venous stenting in locally advanced pancreatic cancer with venous occlusion and associated varices Matthias Ilmer
15.21-15.30 SHP2 regulates CAF activity and adaptive stromal remodeling during vertical RAS pathway inhibition in pancreatic cancer Steffen Johannes Keller
15.30-15.39 Predictors of fecal elastase testing completion in outpatient and inpatient settings: a single center retrospective analysis Arjun Chatterjee
15.45-16.15 IAP – General Assembly
GALATA HALL
10.45-13.00 International Multidisciplinary Consensus Report on Fatty Pancreas: Lessons Learned and Roadmap for the Future Chairs: Vinciane Rebours (Paris, France), J. -Matthias Löhr (Heidelberg, Germany)
10.45-10.50 Welcome & Opening Remarks Vinciane Rebours (Paris, France), J. -Matthias Löhr (Stockholm, Sweden)
10.50-11.00 Fatty Pancreas: Background, Consensus Methodology, and Key Concepts Miroslav Vujasinovic (Stockholm, Sweden)
11.00-11.10 Histopathological Features of Fatty Pancreas Aslıhan Yavaş (Dusseldorf, Germany)
11.10-11.25 Imaging Modalities and Radiological Evaluation of Fatty Pancreas Muşturay Karçaaltıncaba (Ankara, Turkiye)
11.25-11.35 Clinical Implications of Fatty Pancreas in Acute and Chronic Pancreatitis Pramod Garg (New Delhi, India)
11.35-11.45 Fatty Pancreas in Pancreatic Neoplasms: IPMN and PDAC Perspectives Giovanni Marchegiani (Padova, Italy)
11.45-11.55 Metabolic Consequences of Fatty Pancreas: β-Cell Function and Glucose Regulation Laszlo Czako (Szeged, Hungary)
11.55-12.05 Surgical Considerations and Management of Fatty Pancreas Sanjay Pandanaboyana (New Castle, UK)
12.05-12.25 Therapeutic Strategies, Key Conclusions, and Future Directions in Fatty Pancreas Research İhsan Ekin Demir (Munich, Germany)
12.25-13.00 Panel Discussion: Multidisciplinary Perspectives and Audience Q& Chairs and All Speakers
13.00-14.00 Lunch
KADIKÖY HALL
10.45-13.00 TRANSPAN
13:00-14:00 Lunch
14:00-15.45 PANDoRA Consortium
15:45-16:15  Coffee Break
A3 ROOM
07.30-08.30 EPC Public Affairs Committe
10.15-10.45 EPC & JPS

 

STONE Amphitheatre
07.30-08.30 Börek with the Professors
CASE 2
08.30-10.30 Hands-On Workshop
10.30-10.45 Coffee Break
10.45-13.00 Hands-On Workshop
13:00-14:00 Lunch
14:00-15.45 Hands-On Workshop
15:45-16:15  Coffee Break
16.30-17.00 Hands-On Workshop

Bebek Poster Hall / 13.00 – 14.00

*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)
AbsRef Pub Number Title Presenter
Group – 18 Chairs: Bo Kong, Özlem Sönmez
384 POTH-014 Network-based identification of stage-specific interception points in pancreatic disease progression Yan Bi
585 PPCC-065 Injecting Innovation: EUS-Guided Phosphorus-32 as a Local Ablative Boost in Pancreatic Cancer Therapy Rodrigo Montoto Meijide
599 PPCC-066 The role of detective flow imaging- endoscopic ultrasound in the characterization of unexplained biliary strictures: a retrospective study Leila Babaiyan
606 PPCC-067 Beyond Presence: Patterns of Angioinvasion as Determinants of Aggressiveness in Pancreatic Ductal Adenocarcinoma Samuele Grandi
632 PPCC-068 Chemotherapy-induced liver injury during Neoadjuvant Treatment in Pancreatic Cancer: A Systematic Review and Meta-analysis Randomized Controlled Trials Alessio Marchetti
645 PPCC-069 High-grade PanIN/Carcinoma in situ Incidentally Discovered in a Resected Pancreas with IPMN: A Retrospective Radiological Review Yoshihiro Hamada
651 PPCC-070 Distinct Lipid Signatures in Early-Onset Pancreatic Ductal Adenocarcinoma Liu Longyu
653 PPCC-071 Diagnostic work-up of patients with suspected pancreatic cancer: A prospective single-centre study Tamas Hussein
654 PPCC-072 Tumor microbiota profiling identifies microbial signatures associated with clinical and radiological features in locally advanced pancreatic ductal adenocarcinoma Giacomo Marcozzi
660 PPCC-073 Prognostic impact of positive margin location after R1 pancreatic resections: a survival analysis Orfeas Varvarelis
663 PPCC-074 Clinical impact of positive drain fluid amylase after pancreatectomy: association with postoperative complications and hospital stay Vasiliki Alkmini Themelidi
671 PPCC-075 The impact of preoperative biliary drainage on the occurrence of postoperative complications after pancreaticoduodenectomy Vladyslav Bondar
677 PPCC-076 Giant (18 cm) primary epithelioid gastrointestinal stromal tumor of the pancreatic tail: Case Report and Literature Review Vyronas Argyris
678 PPCC-077 Analysis of the diagnostic utility of endosonography-guided biopsy in pancreatic solid lesions Barbara Wlodarczyk
687 PPCC-078 Features of pancreatic cancer in the tunisian population Amal Khsiba
Group – 19 Chairs: Daniel Öhlund, Mert Erkan
784 POTH-024 Fatty changes in resected pancreatic neck Mariia Kiriukova
689 PPCC-079 Use of Dynamic Cell Imaging™ (DCI) with the Van Gogh Platform in EUS-guided Sampling of Pancreatic Solid Lesions: A Feasibility Pilot Study Maria Terrin
711 PPCC-080 A preliminary analysis of the diagnostic performance of a radiological artificial intelligence (AI) tool for the incidental detection of pancreatic lesions on computed tomography Antonella Campisi
712 PPCC-081 Characteristics of pancreatic ductal adenocarcinoma following acute pancreatitis: a multicentric cohort analysis on 1006 cases Ruggero Ponz De Leon Pisani
714 PPCC-082 Use of aspirin, statins, metformin and ace-inhibitors does not affect disease-free, disease-specific and overall survival in patients affected by pancreatic ductal adenocarcinoma Ruggero Ponz De Leon Pisani
715 PPCC-083 PrePANC-NT Trial: Prehabilitation in Patients with Pancreatic Cancer During Neoadjuvant Therapy; Exploring an Understudied Window Ahmet Anil Sahar
717 PPCC-084 The Role of Pancreatic Tumor/Remnant Tissue Density Ratio in Predicting Grade B and C POPF Ulas Utku Sekerci
718 PPCC-085 Perivascular regions show reduced response to neoadjuvant chemotherapy in PDAC with vascular involvement David Zschäpitz
719 PPCC-086 Patterns of recurrence in ampullary carcinoma – A Cross-Validation Study of the German Cancer Registry and an International Multicenter Cohort Julia Straesser
721 PPCC-087 Clinical significance of tumor markers CA 19-9, CA 242, CA 50 and CA 72-4 in the diagnosis and staging of pancreatic cancer Uros Djindjic
724 PPCC-088 Macrophage inhibitory cytokine 1, syncollin, and thrombospondin-2 in the differential diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis Michalina Wieczorek
730 PPCC-089 A rare case of a 7 cm distal pancreatic ductal adenocarcinoma with a central 3 cm osseous metaplasia, oligometastatic to the liver, still alive 9 years after multi-visceral resection, excision of liver metastasis and chemotherapy Sorin Traian Barbu
734 PPCC-090 Endoscopic Ultrasound (EUS) Findings of Metastatic Lesions to the Pancreas: A Retrospective Single-Center Study Nevin Oruç
735 PPCC-091 Indications and prognostic factors in metastatic pancreatic cancer referred for radical treatment – a systematic review and meta-analysis Chiara Maria Scandinavini
736 PPCC-092 Efficacy of immunonutrition in hepatobiliary cancer patients – a systematic review and meta-analysis Bettina Csilla Budai
342 PPED-001 Is the prevalence of the exacerbations of the chronic pancreatitis related to the infectious season? Zofia Oracz
Group – 20 Chairs: Christopher Wolfgang, Orcun Can
163 POTH-006 A rare case of pancreatic mass mimicking malignancy Emine Gökce
741 PPCC-093 Postoperative Pancreatic Fistula and Recurrence in Pancreatic Ductal Adenocarcinoma Hüseyin Fahri Martlı
745 PPCC-094 Liver metastasis and surgery for pancreas adenocarcinoma Ahmet Çoker
748 PPCC-095 Hemopatch and pancreatic fistula Ahmet Çoker
752 PPCC-096 High Early Recurrence Burden in Young Patients with Pancreatic Cancer Following Surgical Resection Hüseyin Fahri Martlı
757 PPCC-097 Diagnostic Laparoscopy in Staging Exocrine Pancreatic Cancer: An Updated Review and Recommendations Emilija Nikolovska Trpchevska
761 PPCC-098 Development and validation of a machine learning model predicting overall survival after resection of adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) Christos Athanasiou
762 PPCC-099 Resection Margin Sites and Their Impact on Oncological Outcomes in Adenocarcinoma Arising from IPMN: Results from an International Multicenter Cohort Study Vivek Peddakota
772 PPCC-100 The impact of neoadjuvant chemotherapy (nCT) on outcomes for patients with resectable pancreatic cancer Ilya Vervekin
773 PPCC-101 Contemporary Adjuvant Chemotherapy for intraductal papillary mucinous neoplasms following pancreatic resection Vivek Peddakota
774 PPCC-102 The “Acıbadem sandwich protocol” – a novel neoadjuvant chemoradiotherapy approach in bordeline resectable and locally advanced pancreatic cancer patients Nur Ramoğlu
785 PPCC-103 Primary Pancreatic Squamous Cell Carcinoma: A rare rntity with unexpected EUS findings David Miguel Ferro Tomás
799 PPCC-104 Comparison of Total Mesopancreatic Excision and Conventional Pancreaticoduodenectomy in the Surgical Treatment of Pancreatic Head Adenocarcinoma: Early Postoperative Outcomes Cihan Ağalar
800 PPCC-105 Up-front Surgery for Anatomically Borderline Resectable and Locally Advanced Pancreatic Cancer (BR/LAPC): Contemporary Real-world Outcomes Zipeng Lu
805 PPCC-106 Failure to Rescue After Pancreatoduodenectomy: A Single-Center Analysis Compared to GAPASURG Data Congde Martin Xu
Group – 28 Chairs: Okan Safak
107 POTH-001 Highly effective but not lifelike? Prehabilitation in pancreatic surgery – Single-center experience Matthias Glanemann
141 POTH-002 Small intestinal bacterial overgrowth (SIBO) and colonic dysbiosis in patients with combined fatty pancreas and metabolic dysfunction-associated steatotic liver disease (MASLD) Nadiia Bieliaieva
144 POTH-003 The disease of Albrecht Dürer Natalya Gubergrits
148 POTH-004 Microbiological Profile and Antimicrobial Resistance Patterns in Walled-Off Pancreatic Necrosis: A Single-Centre Retrospective Study Tom Brand
158 POTH-005 Morphological patterns of inflammatory infiltration and fibrosis of the gastric mucosa in Helicobacter pylori-associated NSAID gastropathies in patients with ischemic heart disease Almaza Madumarova
243 POTH-007 When Is Pancreatic Cancer Surveillance Efficient? A Microsimulation Study of Test Characteristics and Lifetime Risk Oliver White
286 POTH-010 Pancreatic arteriovenous malformations as a manifestation of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): a systematic review Isabel De Jager
380 POTH-012 The Role of Helicobacter pylori in Pancreatic and Hepatic Steatosis Mimoza Kankia
381 POTH-013 Surgical Anatomy of Peripancreatic Vessels in Pancreatic Resections Spiros Delis
423 POTH-016 Bacterial Colonization in Resected Lymph Nodes During Pancreatic Surgery – A Pilot Study Saadet Gurcinar
474 POTH-017 Impact of multimodal prehabilitation on postoperative outcomes after pancreatic resection: design of a prospective randomized controlled trial Stefan Kolcun
530 POTH-018 PancreOS: A network of registries on Pancreatic Cancer Raquel Benitez Dorta
572 POTH-019 Different intracellular pathways to calcium signal generation in pancreatic acinar cells activated by the cancer-promoting receptor for gastrin-releasing peptide (GRP) and by excitation of cholecystokinin (CCK) receptors Muhanad E Salih
580 POTH-020 Diagnostic Performance of EUS versus MRCP for Choledocholithiasis: A Systematic Review Taibe Haziri
652 POTH-021 Building quality improvement in HPB surgery in Ukraine: a nationwide needs assessment survey of surgeons and anesthesiologists Inesa Huivaniuk
672 POTH-022 Trans-anastomotic Stent After Pancreatoduodenectomy: Impact on Early Postoperative Drain Fluid Amylase Aya Maekawa
804 POTH-025 Fatty changes are more frequent in malignant pancreatic diseases Mariia Kiriukova
Group – 33 Chairs: Anna Caterina Milanetto
206 PNET-001 Surgery or surveillance in sporadic Pancreatic Neuroendocrine Neoplasms in patients with age >= 75 years ? Anna Caterina Milanetto
207 PNET-002 Duodenal Neuroendocrine Neoplasms. Surgical treatment and long-term results Anna Caterina Milanetto
313 PNET-003 Pancreatic neuroendocrine tumor with bile duct stenosis: possible origin of the bile duct epithelium Atsuko Kasajima
377 PNET-004 Pancreatic Neuroendocrine Neoplasms: Surgical Results from the Hellenic Pancreatic Neuroendocrine Tumor (HELPNET) Study Group Spiros Delis
388 PNET-005 Laparoscopic Resection of Pancreatic Insulinoma in a Patient with Multiple Endocrine Neoplasia Type 1: A Case Report and Literature Review Hao Luo
434 PNET-006 Pancreatic and ampullary neuroendocrine tumors: diagnosis, staging and management at a Moroccan tertiary center Jaouhara Lahsini
458 PNET-007 Aurora kinase inhibition as a targeted therapy for ARID1A‑deficient gastroenteropancreatic neuroendocrine carcinoma Maria Pacalajova
598 PNET-008 Complex course of incidental pancreatic neuroendocrine tumor and inflammatory bowel disease with repeated surgical complications: a case report Dóra Demeter
644 PNET-009 Two Cases of PP-producing PanNET with Atypical Histopathology and Invasive Character Yoshihiro Hamada
698 PNET-010 Validation of Progression-Free Survival and Other Candidate Surrogate Endpoints for Overall Survival in Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis Yuxin Wang

Moda Poster Hall / 13.00 – 14.00

*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)
AbsRef Pub Number Title Presenter
Group – 24 Chairs: Rup Talukdar, Kazushige Uchida
586 PAPC-047 Interim results of the international LIFESPAN case–control study: lifestyle risk factors in acute pancreatitis Dalma Dobszai
601 PAPC-048 Physiotherapy improves the functional status and physical strength of patients hospitalized with acute pancreatitis Bence Tibor Soós
612 PAPC-049 Development and International Validation of a Deep Learning Model for Acute Pancreatitis Severity Brigitta Teutsch
617 PAPC-050 Microbiological profile and temporal shifts in infected pancreatic necrosis in acute pancreatitis: A single-center descriptive study Rodrigo Montoto Meijide
635 PAPC-051 A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE – 1 year open-label extension Maciej Banach
637 PAPC-052 Plozasiran decreases the risk of acute pancreatitis and may improve quality of life in Familial Chylomicronemia Syndrome Maciej Banach
638 PAPC-053 Lipase Over Amylase in Acute Pancreatitis: A 1,293-Case Retrospective Paula Filipa Rebelo
640 PAPC-054 When Lipase Fails: Predictors of False-Negative Acute Pancreatitis Paula Filipa Rebelo
643 PAPC-055 Economic Impact of a Lipase-Only Diagnostic Strategy in Acute Pancreatitis: A Cost Modelling Analysis Paula Filipa Rebelo
650 PAPC-056 Advances in the prediction of acute pancreatitis severity using machine learning models Ying Lu Huang
674 PAPC-057 Incidence and severity of pancreatic exocrine insufficiency in acute pancreatitis during hospitalization: a prospective observational study Jingwen Rao
675 PAPC-058 Transgastric endoscopic necrosectomy alone for pancreatic necrosis extending to the paracolic gutter in necrotizing pancreatitis: a retrospective cohort study Jingwen Rao
691 PAPC-059 Local complications as the only criterion to define moderately severe acute pancreatitis Juan Lin
692 PAPC-060 Pancreas Divisum: Experience of a Tunisian Center Amal Khsiba
694 PAPC-061 Low-enzyme acute pancreatitis and the limitations of current diagnostic guidelines Gefu Cai
98 PISL-001 Determinants of Islet Yield and Long-Term Metabolic Outcomes After Total Pancreatectomy With Islet Autotransplantation Javed Latif
99 PISL-002 Comparative Outcomes of Total Pancreatectomy with Islet Autotransplantation in Hereditary Versus Non-Hereditary Chronic Pancreatitis: A 30-Year Single-Centre Study Javed Latif
Group – 25 Chairs: Yasar Colak
720 PAPC-062 UICENS Strategy for Treating Infected Pancreatic Necrosis: A 10-Year Single-Center Experience from China Hao Luo
727 PAPC-063 Inflammatory and hematological markers and clinical outcomes in hypertriglyceridemia-related acute pancreatitis: a nationwide multicenter cohort study Yavuz Özden
728 PAPC-064 When Drugs Attack the Pancreas: Unmasking a Hidden Cause of Acute Pancreatitis Ekram Hassan Hasanin
732 PAPC-065 Clinical Characteristics, Timing, and Outcomes of Atypical Hemolytic Uremic Syndrome in Acute Pancreatitis: An Individual Patient-Level Analysis Boglárka Barna
737 PAPC-066 Red Cell Distribution Width at 24 Hours as an Early Predictor of Mortality and Severity in Acute Pancreatitis: A Multicenter Retrospective Cohort Study Mihai Radu Pahomeanu
739 PAPC-067 Prognostic Value of Red Cell Distribution Width to Platelet Ratio in Acute Pancreatitis – A Multicenter Registry-Based Cohort Study Mihai Radu Pahomeanu
740 PAPC-068 Day 1 Nucleated Red Blood Cell Count as a Prognostic Biomarker in Acute Pancreatitis: a Preliminary Result of a Multicenter Retrospective Cohort Study Mihai Radu Pahomeanu
744 PAPC-069 Endosonographic differentiation of acute necrotizing pancreatitis and tumor-induced pancreatitis in the acute phase Elena Mateska
749 PAPC-070 Nutritional status at admission and clinical outcomes in acute pancreatitis: a prospective observational cohort study Olga Julia Zahariev
753 PAPC-071 Role of Lanreotide in the Management of Complex Pancreatic Fluid Collections: A Retrospective Review Mudassar Ghazanfar
759 PAPC-072 Male sex is associated with worse outcomes in acute pancreatitis: post-hoc analysis of the WATERLAND randomized trial Lucía Guilabert
777 PAPC-073 Machine Learning-Based Risk Stratification in Acute Pancreatitis: Development of a Balanced Random Forest Model for Predicting Severity of Pancreatitis and Critical Care Admission Christos Athanasiou
778 PAPC-074 Depression, Anxiety, and Outcomes in Acute Pancreatitis: A Prospective Observational Study Tibor Dániel Fehér
796 PAPC-075 Effect of methionine containing antioxidant cocktail on recurrence of acute pancreatitis in children Pullara Kashif Suleman
100 PISL-003 Portal venography and portal venous pressure assessment following total pancreatectomy and islet autotransplantation using a recanalised umbilical vein catheter Javed Latif
161 PISL-004 A 30-Year Multidisciplinary Framework for Assessment and Consent in Total Pancreatectomy with Islet Autotransplantation Javed Latif
769 PISL-007 Islet autotransplantation in pancreatic trauma: evaluating feasibility, safety, and metabolic outcomes after pancreatic resection Sanjay Pandanaboyana
Group – 26 Chairs: Yasar Colak, Giovanni Marchegiani
102 PCYS-001 Obesity as a Risk and Prognostic Factor for Disease Progression in Intraductal Papillary Mucinous Neoplasm (IPMN): A Systematic Review and Meta-analysis Charlotte Gustorff
152 PCYS-003 Assessing surveillance for branch duct IPMN: Number needed to screen and standardized incidence ratio analysis Julia Moghadampour
237 PCYS-004 Treatment of Pancreatic Pseudocysts Under Endosonographic Guidance Igor Khomiak
263 PCYS-005 Pancreatic acinar cell cystadenoma: single-center experiences and a systematic review Miroslav Vujasinovic
346 PCYS-007 Risk factors associated with high-grade dysplasia and adenocarcinoma in mucinous cystic neoplasm of the pancreas Alejandro Gutierrez Castillo
610 PSUR-048 Unraveling the protective effect of female sex on outcome after pancreatoduodenectomy: less complications or smaller impact? for the Dutch Pancreatic Cancer Group Greta Donisi
621 PSUR-049 Comparison of surgery outcomes for pancreatic ductal adenocarcinoma according to tumour location: eleven years of experience in a tertiary hospital Núria Llorach Perucho
622 PSUR-050 Comparison of pancreaticoduodenectomy with and without mesenteric-portal venous resection in pancreatic ductal adenocarcinoma: 11 years of experience in a tertiary institution Francisco Garcia Borobia
626 PSUR-051 Standardising Extravasation Injury Management: A Retrospective Audit & Future Improvements Berin Gorgun
636 PSUR-052 The impact of inflammation and biliary microbiology on postoperative morbidity after cholecystectomy – a single-center retrospective cohort study Patrick Hofmockel
646 PSUR-053 Perioperative transfusions of blood products and the effect on postoperative morbidity and mortality in pancreatic head resections- A unicenter, retrospective analysis Isabel Kraemer
659 PSUR-054 The burden of vascular resection in pancreatic surgery: myth or reality Vanessa Cusano
667 PSUR-055 Preoperative GNRI fails to predict clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy and distal pancreatectomy for PDAC: an external validation study Miguel Fróis Borges
668 PSUR-056 Artificial intelligence–derived inflammatory and nutritional profiles identify high-risk patients undergoing pancreatic cancer resection Miguel Fróis Borges
Group – 27 Chairs: Johanna Laukkarinen, Sohei Satoi
639 PCYS-011 Scoping review of cost-effectiveness of surveillance of intraductal papillary mucinous neoplasms Dana Sochorova
670 PCYS-012 ATHENA: A Multimodel AI Decision-Support Tool for Multidisciplinary Evaluation of Pancreatic Cysts Claudio Ricci
747 PCYS-013 MACHINE-LEARNING-POWERED ENDOSCOPIC ULTRASOUND DETECTS MORPHOLOGICAL FEATURES FOR PREDICTING MALIGNANCY IN IPMNs: RESULTS FROM THE “IMAGE” STUDY FROM A TERTIARY REFERRAL CENTER Matteo Tacelli
750 PCYS-014 Can we predict biopsy accuracy in IPMNs? Preoperative prediction of cytology-histology concordance combining EUS-FNA and a machine learning approach Matteo Tacelli
802 PCYS-015 Single-center experience with endoscopic management of demarcated walled-off pancreatic necrosis (WOPN) Dominik Horváth
669 PSUR-057 Frailty predicts postoperative mortality in pancreatic resection for cancer Miguel Fróis Borges
681 PSUR-058 Intraoperative Indocyanine Green Angiography to Prevent Functional Deficit after Tail-Preserving Pancreatectomy – An Experience of a Tertiary Care Centre of Nepal Prabir Maharjan
682 PSUR-059 CRP kinetics and NLR as early predictors of clinically relevant POPF following pancreatic surgery Mario Gruppo
704 PSUR-060 Toward mechanically realistic pancreatic surgery simulation: multi-modal characterization of relevant tissues Arianna Callera
707 PSUR-061 Concomitant Major Complication (CMC) score defines postoperative trajectories and outcomes after Pancreatoduodenectomy Alice Cattelani
725 PSUR-062 Simultaneous or staged liver resection in the treatment of synchronous colorectal cancer metastases Predrag Zdujic
731 PSUR-063 Pancreatic metastases: retrospective case series from a tertiary referral center Konstantinos Iliakopoulos
767 PSUR-064 Comparison of different types of pancreatic anastomoses after pancreaticoduodenectomy (modified Blumgart anastomosis vs invagination pancreaticojejunostomy) Ilya Vervekin
794 PSUR-065 Double roux reconstruction to reduce pancreatobiliary reflux and its potential role in preventing malignancy after pancreatoduodenectomy Eylül Köseler
Group – 31 Chairs: Jayanta Samanta, Miroslav Vujasinovic
526 PCYS-008 Elevated CA19-9 is a good predictor of adverse long-term outcomes after pancreatic resection for adenocarcinoma arising from IPMN. Results from an international multicenter cohort study Vivek Peddakota
536 PCYS-009 Rethinking the Role of Acute Pancreatitits in Intraductal Papillary Mucinous Neoplasms: A Multicenter Evaluation of Radiologic, Clinical, and Biological Predictors of Neoplastic Progression Riccardo Pellegrini
238 PCYS-010 Risk Stratification of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasm Using 2024 Kyoto Guidelines: Impact of Worrisome Features Jisun Lee
614 PEND-032 EUS-Guided gastroenterostomy versus enteral stenting for malignant gastric outlet obstruction in pancreatic cancer: A real-world comparative study Sofía Barral Diaz
615 PEND-033 Choosing the Optimal EUS-Guided Drainage in Malignant Distal Biliary Obstruction: Choledochoduodenostomy vs gallbladder drainage José Lariño Noia
673 PEND-034 From Pixels to Decision-Making: Utilizing Multi-scale Attention and Self-supervised Baseline Models to Achieve Pathologist Cognitive Workflow in Pancreatic ROSE Jie Hao
696 PEND-035 Microbial Profile of Bile Cultures in Patients with Cholangitis Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Systematic Review and Meta-Analysis Yoon Kee Beck
701 PEND-036 EUS-guided HepaticoGastrostomy in pancreatobiliary malignancies: prospective assessment of efficacy and safety according to indication and anatomy Roberto Junior Ruggiero
766 PEND-038 Clinical outcomes of EUS-guided multiple transluminal gateway drainage for walled-off pancreatic necrosis and pseudocysts: a single-center experience Patryk Kaczor
781 PEND-039 Thirty-day hospital admission following Outpatient ERCP: Safety Profile and Predictive Factors David Miguel Ferro Tomás
787 PEND-040 Safety and efficacy of precut techniques for biliary cannulation in Outpatient ERCP David Miguel Ferro Tomás
577 PIMG-003 Comparative assessment of pancreatic stiffness in fatty pancreas vs. healthy controls using ultrasound elastography Emilija Nikolovska Trpchevska
716 PIMG-005 Radiomics and Artificial Intelligence in Pancreatic Endoscopic Ultrasound: Can We Detect Cancer Before It Becomes Visible? Irina Florina Cherciu Harbiyeli
Group – 32 Chairs: Stephen Pandol
182 PEDI-001 Clinical significance and accuracy of continuous glucose monitoring in pancreatectomy patients Yoo Jin Choi
250 PEDI-002 Real-world evaluation of suspected pancreatic exocrine insufficiency and generation of a reasonable workup – a cohort study from a large pancreatic disease center in Germany Jakob Vielhauer
142 PEPI-002 Exocrine pancreatic insufficiency or lactase deficiency: differential diagnosis Nadiia Bieliaieva
150 PEPI-004 Long-term Nutritional Outcomes After Distal Pancreatectomy for Benign Pancreatic Cysts: Impact of Pancreatic Enzyme Replacement Therapy Yoonchan Lee
205 PEPI-006 Pancreatic exocrine insufficiency after esophageal and gastric surgery: the PEGAS study Miroslav Vujasinovic
281 PEPI-007 Comparative renal effectiveness of newer glucose-lowering drugs with metformin in new-onset diabetes after pancreatitis patients: a target trial emulation cohort study Di Wu
307 PEPI-008 Features of exocrine insufficiency in long-term follow-up after proximal pancreatic resection Yulia Osipenko
318 PEPI-009 Symptoms of Pancreatic Exocrine Insufficiency Correlate with Stool Consistency Rather Than EUS Findings Joowon Chung
371 PEPI-010 Diagnostic Performance and Cost Implications of Fecal Elastase in Evaluating Steatorrhea and Exocrine Pancreatic Dysfunction Motaz Ashkar
421 PEPI-011 Low bone mineral density and fracture risk in chronic pancreatitis: The impact of pancreatic exocrine insufficiency Andreia Rei
583 PEPI-013 Familial fatty pancreas due to transheterozygous mutations in MECOM and CELA3B  Maren Ewers
611 PEPI-014 Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: a systematic review and meta-analysis Orsolya Eperjesi
791 PEPI-017 Pancreatic Exocrine Insufficiency as a Marker of Disease Progression in IPMN Surveillance: IPEX Study Giacomo Deiro

Beşiktaş Poster Hall / 13.00 – 14.00

*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)
AbsRef Pub Number Title Presenter
Group – 21 Chairs: Andrea Geisz-Fremy
482 PPCE-049 Interim outputs of the United Kingdom Early Detection Initiative for pancreatic cancer Lucy Oldfield
484 PPCE-050 Deciphering the Genomic Drivers of Neural Invasion in Pancreatic Cancer Basak Kavaklioglu
488 PPCE-051 A circulating protein signature of pancreatogenic disease detectable up to five years before pancreatic cancer diagnosis Irena Stefanova
489 PPCE-052 An advanced preclinical model for testing combination therapy in pancreatic cancer using a dynamic culture platform Verona Buocikova
494 PPCE-053 ROR1 Expression in Lymph Nodes, Tumor Tissue, and Immune Cells as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Anke Mittelstädt
498 PPCE-054 Deep learning–driven identification of peripherally restricted NPY1R antagonists to disrupt nerve-tumor crosstalk in pancreatic ductal adenocarcinoma Esra Nalbat
510 PPCE-055 Integrative molecular analysis of pancreatic cancer precursor lesions: predictive models for biological aggressiveness and tumor development Raka Aziz
531 PPCE-057 Decitabine reshapes the transcriptional response to gemcitabine in orthotopic MIAPaCa-2 pancreatic cancer xenografts Bozena Smolkova
533 PPCE-058 Targeting VMP1 to Overcome Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma Maria Ines Vaccaro
551 PPCE-060 GLOPH3-ERK1/2-E2F1 positive feedback loops promote pancreatic cancer progression Wang Zheng
552 PPCE-061 The Fas receptor promotes neural invasion by inducing a shift from apoptotic to migratory signaling in pancreatic cancer Clara M. Müller
553 PPCE-062 Integrated Single-Cell Analysis Identifies CD55 as a Mediator of Neoadjuvant Chemotherapy Resistance in PDAC Zongyao Chen
575 PPCE-063 Schwann Cell derived Chromosome 4 Chemokines modulate Cancer Cell Viability Mara R Goetz
576 PPCE-064 Knock-out of mitophagy receptors Bnip3 and Nix results in increased therapy response of murine pancreatic cancer cells Simon Knoll
587 PPCE-065 Immunomodulatory impact of PTPN11/SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer Asma Alrawashdeh
Group – 22 Chairs: Heiko Witt
590 PPCE-066 Genome-wide CRISPR/cas9 screening for oxaliplatin resistance in pancreatic cancer Jung Won Chun
603 PPCE-067 Micro-CT analysis can distinguish features of PDAC: preliminary experience Kaisa Tyrväinen
604 PPCE-068 Multi-trait genome-wide association analysis identifies novel susceptibility loci for pancreatic cancer Yongping Chen
609 PPCE-069 Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated to an aggressive tumor microenvironment Greta Donisi
623 PPCE-070 The CTRB2del Variant Confers Increased Risk of Pancreatic Ductal Adenocarcinoma in the Hungarian Population Sarah Ammar Khodja
628 PPCE-071 Combating Chemoresistance in Pancreatic Cancer: Insights from Transcriptomics and dCK-Independent Therapy Giulia Lencioni
629 PPCE-072 The roles of Galnt2 and St3gal6 genes on neural invasion in pancreatic cancer Alper Dogruoz
634 PPCE-073 Integrative CUT&RUN and RNA-seq Analyses Reveal STAT3-Dependent Regulatory Networks in IL-17–Stimulated Pancreatic Acinar Cells Mahnoosh Ostadreza
641 PPCE-074 Exosome-driven schwann cell–cancer cell communication promotes pancreatic cancer aggressiveness Didem Karakas
647 PPCE-075 The impact of RNF43 mutation on the tumor-stroma crosstalk during earlier pancreatic carcinogenesis Matthäus Felsenstein
648 PPCE-076 The mechanism of macrophage-induced PDAC cell senescence driven by ENO1-mediated histone lactation driving pancreatic cancer stemness Luying Huang
664 PPCE-077 Early neural remodeling initiates at the Acinar-to-Ductal Metaplasia stage in pancreatic carcinogenesis Alper Dogruoz
697 PPCE-079 Background. Pancreatic ductal adenocarcinoma (PDAC) is characterized by an aggressive clinical course and profound immunotherapy resistance, driven largely by an immunosuppressive tumor microenvironment (TME) dominated by tumor-associated macrophages Svetlana M. Gramatiuk
700 PPCE-080 Significance of lncRNAs in diagnosis and prognosis of pancreatic cancer Nevin Oruc
703 PPCE-081 Which sugar is sweeter for pancreatic cancer? Nevin Oruc
Group – 23 Chairs: Didem Karakas Zeybek, Ivonne Regel
297 PGEN-002 Germline genetic variants associated with chemotherapy response and survival in non-metastatic pancreatic ductal adenocarcinoma Manuel Gentiluomo
461 PGEN-003 Rare variant analysis suggests ASIC2 and KCNJ2 as candidate genes for pancreatic cancer risk in the UK Biobank cohort study Emma Barreto
602 PGEN-005 Dissecting pancreatic ductal adenocarcinoma genetic architecture through fine-mapping of susceptibility loci Cosmeri Rizzato
630 PGEN-007 Refining Pancreatic Cancer Surveillance Through Context-Aware Germline Variant Interpretation William Greenhalf
662 PGEN-009 NR5A2–CTRB2 genetic interaction increases PDAC risk by impairing pancreatic stress responses Sarah Klauss
746 PGEN-010 Clinical Relevance of Germline CHEK2 and CDKN2A Variants in Pancreatitis and Pancreatic Cancer Stanislaw Zbigniew Gluszek
793 PGEN-012 The role of extrachromosomal DNAs (ecDNAs) in chemocytotoxic resistance in pancreatic cancer Sadaf Shabbir Mughal
722 PPCE-082 The lncRNA within small extracellular vesicles promotes the neuron-cancer crosstalk in pancreatic cancer Linhan Ye
723 PPCE-083 Single-cell profiling identifies MMP1-high inflammatory CAFs associated with neoadjuvant chemotherapy resistance in pancreatic ductal adenocarcinoma Yihong Cai
733 PPCE-084 Neuropeptide Y Promotes Tumor–Nerve Crosstalk and Neural Invasion in Pancreatic Ductal Adenocarcinoma Shenghan Wang
756 PPCE-085 Visualizing pancreatic neural structures using Golgi-Cox staining method Alper Dogruoz
764 PPCE-086 Mechanisms for stroma-induced secondary chemoresistance in pancreatic adenocarcinoma Corinne Bousquet
771 PPCE-087 LAMA3 and LAMA4 are upregulated and prognostically significant in pancreatic cancer Nevin Oruc
775 PPCE-088 NOL4 is a tumor suppressor gene that plays critical role in chronic pancreatitis related oncogenesis Nevin Oruc
792 PPCE-089 Tumor-Educated Platelets Acquire PDAC-Associated RNA: A Multicohort Diagnostic Signature with in vitro Confirmation Aldo Pastore
798 PPCE-090 Deep learning–enabled multiomics reveals neural drivers of perineural invasion in PDAC Raphael Kfuri Rubens
Group – 29 Chairs: Ujjwal Mahajan, Yetiş Gültekin
208 PAPE-001 Mitigating organ failure with a novel oral anti-lipase treatment targeting gut lymph in experimental severe acute pancreatitis John Windsor
227 PAPE-002 Proteomic Profiling Reveals Distinct Sex-Specific Molecular Mechanisms and Inflammatory Pathways in Severe Acute Pancreatitis Aditi Bhargava
233 PAPE-003 Effects of GLP-1 Receptor Agonists on Secretagogue-induced Acute Pancreatitis in Mice Rebecca Reardon Lochbaum
270 PAPE-004 Extracellular vesicle–mediated inflammation in acute pancreatitis is attenuated by Lactated Ringer’s solution: involvement of protein lactylation Olga Armengol Badia
277 PAPE-005 Pancreatic tissue remodeling in experimental pancreatitis is regulated by activation and recruitment of systemic immune cells via the CXCR3 chemokine system Juliane Glaubitz
325 PAPE-006 Differential regulation of pancreatic duct HCO3 secretion by inflammatory cytokines Mingjuan Li
328 PAPE-007 Role of the ER-cargo protein CLN8 in the pathophysiology of acute pancreatitis Lukas Zierke
379 PAPE-008 The inhibition of matrix-metalloproteases restricts the immune cell infiltration and ameliorates the disease severity in acute pancreatitis Shenja Buchholz
401 PAPE-010 GLP-1 receptor agonists induce non-inflammatory pancreatic hypertrophy and ameliorate acute pancreatitis in mice Zhengyang Fan
414 PAPE-011 Interleukin-1 family cytokines regulate pancreatic fibroblast activation and immune cell recruitment in experimental acute pancreatitis Ben Lewin Becker
451 PAPE-012 Expression and Functional Role of H2S-Producing Enzymes in Pancreatic Acinar Cell Injury Erik Orján
456 PAPE-013 Mitigating ferroptosis-induced cellular damage in mouse pancreatic acinar cells Bálint Sándor
483 PAPE-014 Hepatic metabolite N-acetylaspartic acid alleviates acute pancreatitis by restoring mitophagy via BCL2L13 Shiyu Liu
516 PAPE-015 Body Mass Index and Psychological Alterations in Patients with Acute Pancreatitis Zsofia Nemeth
676 PAPE-016 Therapeutic Inhibition of Pancreatic Triglyceride Lipase Ameliorates Hypertriglyceridemic Pancreatitis in mice Jingwen Rao
742 PAPE-017 The pancreatic phenotype of CftrΔpanc mice is driven by the ductal compartment Henrik Einwächter
Group – 30 Chairs: Raghu Kalluri 
160 PCPE-001 Therapeutic targeting of secreted osteopontin attenuates fibrogenesis in experimental chronic pancreatitis Emine Gökce
175 PCPE-002 Immune-related gene signatures and immune cell infiltration in chronic pancreatitis: an integrated bioinformatics analysis Xiaobo Wang
248 PCPE-003 Plasminogen activator inhibitor-1 as a Potential Antifibrotic Target in Chronic Pancreatitis Tünde Molnár
276 PCPE-004 Cholesterol-Mediated communications between acinar cells and β cells in chronic pancreatitis Yitian Zhou
293 PCPE-005 Aptamer-aided anti-inflammatory programming of resident tissue macrophages for recuperation of chronic pancreatitis Jianying Xu
301 PCPE-006 Decoding Mesenchymal Control of Chronic Pancreatitis via Prrx1⁺ Lineage Tracing and Single-Cell Profiling Ruoxuan Dai
339 PCPE-007 The management of pancreaticopleural fistulas: a single centre case series Madhav Sanatkumar Dave
375 PCPE-008 Investigating changes in endocrine function in a mouse model of chronic pancreatitis Gergely Koszta
455 PCPE-009 Restoring ductal CFTR function as a disease-modifying strategy in chronic pancreatitis Tamara Madácsy
466 PCPE-010 Impact of TRPA1 on Acute Injury and Fibrotic Remodeling in Pancreatitis Ola Salamah
471 PCPE-011 A high-fat diet is insufficient to drive pancreatic intraepithelial neoplasia from acinar-to-ductal metaplasia Cecile Haumaitre
486 PCPE-012 IL-4/IL-13/STAT6 signalling regulates fibrogenesis and organ regeneration via suppression of the IL-6/STAT3 pathway during chronic pancreatitis Matthias Sendler
490 PCPE-013 Production of Anti-CX3CR1 Monoclonal Antibody for Use in the Preclinical Treatment of Chronic and Acute Pancreatitis Tayyar Emir Gözeler
538 PCPE-014 Pancreatitis leaves an epigenetic imprint on acinar cells that shapes regeneration and plasticity Yiming Zhang
658 PCPE-015 A CX3CL1–CX3CR1–Driven Neuro-Immune Circuit Amplifies Pain in Pancreatitis and Offers a Druggable Therapeutic Entry Point Ibrahim Halil Gürcinar
751 PCPE-016 APOBEC3A is a molecular link between chronic inflammation and immune activation, driving a feed-forward loop that exacerbates pancreatic injury and promotes mutagenesis Intisar Salim
782 PCPE-017 Re-evaluating the role of TRPV6 deficiency in human and mouse pancreatitis Mate Sandor
image_pdf